(Q37895250)

24 August 2017

1 reference

title

Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis (English)

1 reference

24 August 2017

1 reference

David L Scott

1

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1121-1132

1 reference

https://scigraph.springernature.com/pub.10.2165/11591480-000000000-00000

24 August 2017

exact match

0 references

cites work

Syk kinase as a treatment target for therapy in autoimmune diseases

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Healing the Syk through kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Tyrosine kinase SYK: essential functions for immunoreceptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Therapeutic targeting of Syk in autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Clinical effectiveness of biologics in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Spleen tyrosine kinases: biology, therapeutic targets and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591480-000000000-00000

Treating inflammatory arthritis early

21 January 2018

1 reference

12 December 2020

Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis

1 reference

12 December 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Small molecule challenges dominance of TNF-alpha inhibitors

1 reference

12 December 2020

Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

1 reference

12 December 2020

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

1 reference

12 December 2020

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

12 December 2020

Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases

1 reference

12 December 2020

10.2165/11591480-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1037454435

0 references

1 reference